Quantcast
Last updated on April 19, 2014 at 13:20 EDT

Latest Acacia Pharma Stories

2013-10-30 04:21:57

CAMBRIDGE, England, October 30, 2013 /PRNewswire/ -- Acacia Pharma, a pharmaceutical company specialising in the development of drugs for supportive care, announces the initiation of a Phase II study of APD403 in the prevention of chemotherapy-induced nausea & vomiting (CINV). CINV remains a clinically significant problem in cancer patients receiving emetogenic chemotherapy despite the availability of a range of anti-emetic medications. CINV occurs in approximately...

2013-10-15 04:21:08

CAMBRIDGE, England, October 15, 2013 /PRNewswire/ -- Acacia Pharma, a pharmaceutical company specialising in the development of drugs for supportive care, announces positive results from its Phase II study of APD515 for the treatment of xerostomia (dry mouth) in advanced cancer patients. The study showed that APD515 significantly reduced the symptoms of dry mouth (the primary endpoint) compared to placebo. APD515 is an optimised oromucosal (liquid) formulation of a currently...

2013-09-17 04:22:19

CAMBRIDGE, England, September 17, 2013 /PRNewswire/ -- Acacia Pharma, a pharmaceutical company specialising in the development of drugs for supportive care, announces the initiation of two pivotal Phase 3 studies of APD421 in the prevention of post-operative nausea & vomiting (PONV). PONV remains a clinically significant problem in patients undergoing major surgery, despite the availability of a range of anti-emetic medications. The Phase 3 studies are taking place...

2013-09-03 04:21:17

CAMBRIDGE, England, September 3, 2013 /PRNewswire/ -- Acacia Pharma, a pharmaceutical company specialising in the development of drugs for supportive care, announces it has raised GBP15 million (~$23.5 million) in a Series B financing led by Fidelity Biosciences and Novo A/S. Current investors Gilde Healthcare and Lundbeckfond Ventures also participated in the round. Dr Alex Pasteur of Fidelity Biosciences and Dr Martin Edwards of Novo A/S have joined the Board of Acacia...

2012-05-28 02:20:47

CAMBRIDGE, England, May 28, 2012 /PRNewswire/ -- Acacia Pharma announces positive results from its Phase II study of APD421, in the prevention of post-operative nausea & vomiting (PONV). The study showed that APD421 significantly reduced the incidence of nausea and vomiting compared to placebo in adult surgical patients at moderate-to-high risk of suffering PONV. Vomiting and especially nausea remain a major problem for patients after surgical operations, despite the...

2011-03-31 08:00:00

CAMBRIDGE, England, March 31, 2011 /PRNewswire/ -- - Funds to be Used to Complete Two Phase II Programmes Acacia Pharma, a pharmaceutical company specialising in the development of drugs for cancer supportive care, announces it has successfully closed a funding round, raising a total of $10 million. New investor Lundbeckfond Ventures joins Gilde Healthcare in this Series A financing. Acacia Pharma will use the proceeds to complete Phase II development of its two lead...